Lacosamide Medical Valley (Lacosamide)

Lacosamide is an antiepileptic medication indicated for several seizure types.

• Partial‑onset seizures: provides adjunctive control of focal seizures when added to existing therapy.
• Primary generalized tonic‑clonic seizures: used as add‑on therapy to reduce seizure frequency.
• Epilepsy in pediatric patients: approved for use in children four years of age and older as part of combination treatment.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyper‑excitable neuronal membranes and reducing repetitive neuronal firing. This modulation diminishes the propagation of epileptiform activity without affecting normal neuronal function, contributing to seizure control.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate stomach upset.
• Headache: intermittent pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Vision changes: blurred or double vision.
• Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects

• Cardiac arrhythmia: abnormal heart rhythm, including PR‑interval prolongation.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Respiratory depression: difficulty breathing, especially when combined with other depressants.
• Liver enzyme elevation: significant increase in hepatic transaminases.

When prescribing Lacosamide, clinicians should consider several safety measures.

• Cardiac monitoring: assess ECG for PR‑interval changes before and during therapy.
• Renal function: adjust dose in patients with severe renal impairment.
• Hepatic function: monitor liver enzymes in patients with existing liver disease.
• Concomitant CNS depressants: use caution when combined with other sedating agents.
• Pregnancy: evaluate risk‑benefit ratio; limited data available.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid)

• Carbamazepine: may reduce lacosamide plasma levels, decreasing efficacy.
• Phenytoin: can lower lacosamide concentrations, compromising seizure control.
• Strong CYP2C19 inhibitors: may increase lacosamide exposure, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Other sodium‑channel blockers (e.g., lamotrigine): may enhance CNS side effects.
• Opioids or benzodiazepines: increased sedation and respiratory depression.
• Anticoagulants: potential for altered bleeding risk, monitor INR if applicable.